https://pharmadog.xyz/news/123082 pharmadog en 2026-08-10T11:53:00.000Z Latigo and BlossomHill file Nasdaq IPO plans to fund pain and cancer pipelines https://pharmadog.xyz/news/222803 pharmadog en 2026-08-10T11:38:20.000Z STAT+: Heart failure drug from Tenax Therapeutics fails in pivotal study https://pharmadog.xyz/news/222759 pharmadog en 2026-08-10T11:31:25.000Z Silence spells out Phase 2 success for gene-silencing drug in rare blood cancer https://pharmadog.xyz/news/222804 pharmadog en 2026-08-10T11:31:00.000Z STAT+: Silence Therapeutics aims at Takeda with new data in rare blood cancer https://pharmadog.xyz/news/222784 pharmadog en 2026-08-10T11:20:01.000Z BioMarin axes asset from $270M Inozyme takeover, ending run in rare metabolic indication https://pharmadog.xyz/news/222651 pharmadog en 2026-08-10T11:00:22.000Z BioNTech veteran secures $25M seed round for virtual cancer surveillance startup https://pharmadog.xyz/news/222547 pharmadog en 2026-08-10T10:42:13.000Z Denali Therapeutics' Avlayah generates $3.6M in Q1, beating forecasts https://pharmadog.xyz/news/222203 pharmadog en 2026-08-10T09:00:00.000Z Early regulatory operations planning key to submission-ready dossiers https://pharmadog.xyz/news/222185 pharmadog en 2026-08-10T08:30:00.000Z Safety concerns emerge as radiopharmaceuticals advance in cancer trials https://pharmadog.xyz/news/222184 pharmadog en 2026-08-10T08:30:00.000Z Global Ebola preparedness fixated on one strain, leaving gaps for other species https://pharmadog.xyz/news/222183 pharmadog en 2026-08-10T08:30:00.000Z China clamps down on investigator-initiated clinical trials, tightening oversight https://pharmadog.xyz/news/222186 pharmadog en 2026-08-10T08:30:00.000Z States urged to use low-cost, scalable outreach for Medicaid enrollees facing 2027 eligibility changes https://pharmadog.xyz/news/221739 pharmadog en 2026-08-10T07:12:00.000Z AGC Biologics targets in-vivo gene therapies with stable producer lines and next-gen purification https://pharmadog.xyz/news/222330 pharmadog en 2026-08-10T05:06:00.000Z Arpeggio plays final chord as biotech disbands on poor prospects for Nrf2 program https://pharmadog.xyz/news/222734 pharmadog en 2026-08-10T04:36:00.000Z Silence brings the noise to Takeda with phase 2 blood cancer win https://pharmadog.xyz/news/222114 pharmadog en 2026-08-10T04:29:00.000Z aTyr lays off 60% of workforce to fund 2nd attempt at phase 3 success for lung disease drug https://pharmadog.xyz/news/221039 pharmadog en 2026-08-10T04:04:00.000Z Biogen’s ALS drug shows symptom improvement in some patients three years after approval https://pharmadog.xyz/news/221040 pharmadog en 2026-08-10T04:03:00.000Z BMS's Cobenfy faces market hurdles as side effects limit uptake, MapLight eyes opportunity https://pharmadog.xyz/news/221041 pharmadog en 2026-08-10T04:02:00.000Z Eli Lilly's $3.8 B acquisition of AtaiBeckley signals growing confidence in psychedelics for depression https://pharmadog.xyz/news/220191 pharmadog en 2026-08-09T23:16:45.000Z Sanofi reports shortages of Myozyme and Nexviazyme for Pompe disease after FDA manufacturing warning https://pharmadog.xyz/news/220793 pharmadog en 2026-08-09T04:00:00.000Z Taylor Fresh Foods recalls jalapeño-containing products over possible Salmonella contamination